- Home
- OTLY vs ACIU Comparison
OTLY vs ACIU Comparison
Compare OTLY & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- ACIU
- Stock Information
- Founded
- OTLY 1994
- ACIU 2003
- Country
- OTLY Sweden
- ACIU Switzerland
- Employees
- OTLY N/A
- ACIU N/A
- Industry
- OTLY Packaged Foods
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- OTLY Consumer Staples
- ACIU Health Care
- Exchange
- OTLY Nasdaq
- ACIU Nasdaq
- Market Cap
- OTLY 256.5M
- ACIU 247.4M
- IPO Year
- OTLY 2021
- ACIU 2016
- Fundamental
- Price
- OTLY $9.27
- ACIU $1.64
- Analyst Decision
- OTLY Buy
- ACIU Strong Buy
- Analyst Count
- OTLY 4
- ACIU 2
- Target Price
- OTLY $19.75
- ACIU $12.00
- AVG Volume (30 Days)
- OTLY 108.9K
- ACIU 176.4K
- Earning Date
- OTLY 04-30-2025
- ACIU 05-12-2025
- Dividend Yield
- OTLY N/A
- ACIU N/A
- EPS Growth
- OTLY N/A
- ACIU N/A
- EPS
- OTLY N/A
- ACIU N/A
- Revenue
- OTLY $823,666,000.00
- ACIU $30,136,397.00
- Revenue This Year
- OTLY $3.92
- ACIU N/A
- Revenue Next Year
- OTLY $6.14
- ACIU $676.94
- P/E Ratio
- OTLY N/A
- ACIU N/A
- Revenue Growth
- OTLY 5.15
- ACIU 84.51
- 52 Week Low
- OTLY $6.00
- ACIU $1.43
- 52 Week High
- OTLY $26.80
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- OTLY 50.76
- ACIU 41.18
- Support Level
- OTLY $8.40
- ACIU $1.45
- Resistance Level
- OTLY $8.90
- ACIU $1.68
- Average True Range (ATR)
- OTLY 0.43
- ACIU 0.10
- MACD
- OTLY 0.04
- ACIU 0.04
- Stochastic Oscillator
- OTLY 76.79
- ACIU 65.63
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.